Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

8 results
Display

Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review

Singh P, Nambirajan A, Gaur MK, Raj R, Kumar S, Malik PS, Jain D

Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an aggressive subtype of inflammatory myofibroblastic tumor (IMT) harboring anaplastic lymphoma kinase (ALK) gene fusions and is associated with high risk of local recurrence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation

Zhao S, Liu W, Li S, Shi T, Chen Q, Li Q, Sun L, Ren D, Song Z, Huang C, Xu S

A 61-year-old male patient was simultaneously diagnosed with lung adenocarcinoma and inflammatory myofibroblastic tumor (IMT). The lung adenocarcinoma and IMT harbored two distinct types of ALK translocation, LOC101927285-ALK, and TPM3-ALK,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rapidly Destructive Arthrosis of Knee Following Treatment of Crizotinib in a Patient with Non-Small-Cell Lung Cancer

Hwang JT, Choi JH, Park CH, Yoon KJ, Lee YT, Do JG

Rapidly destructive arthrosis is a rare syndrome characterized by narrowing of the joint space and rapid joint destruction within 6∼12 months. A 62-year-old woman with anaplastic lymphoma kinase rearranged non-small-cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki , Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T

PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Uterine Cervix Metastasis in Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Rearrangement

Choi S, Park CK, Kim SY, Yoon HK, Ro SM, Nam Y

The importance of anaplastic lymphoma kinase (ALK) as an oncogene in non-small cell lung cancer (NSCLC) has emerged as a major concern due to a dramatic clinical effect of targeted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Successful Treatment of Crizotinib-Associated Severe Hepatotoxicity in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Jin J, Ahn SY, Kim S, Lee HS, Oh IJ, Kim KS, Kim YC, Choi YD

  • KMID: 1910333
  • Soonchunhyang Med Sci.
  • 2014 Jun;20(1):35-38.
Crizotinib-associated severe hepatotoxicity has been rarely reported and experts recommended stopping crizotinib treatment in patients with grade 3/4 transaminase elevation. We experienced a case of anaplastic lymphoma kinase-positive non-small cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr